These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 20669296)
41. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
42. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Libman I; Gawel MJ; Riopelle RJ; Bouchard S Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120 [TBL] [Abstract][Full Text] [Related]
43. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. Goetz CG; Tanner CM; Gilley DW; Klawans HL Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764 [TBL] [Abstract][Full Text] [Related]
44. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700 [TBL] [Abstract][Full Text] [Related]
45. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
46. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100). Cedarbaum JM; Kutt H; McDowell FH Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762 [TBL] [Abstract][Full Text] [Related]
48. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease. Olanow CW; Alberts MJ Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266 [No Abstract] [Full Text] [Related]
49. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023 [TBL] [Abstract][Full Text] [Related]
50. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Meppelink AM; Nyman R; van Laar T; Drent M; Prins T; Leenders KL Mov Disord; 2011 Feb; 26(2):331-4. PubMed ID: 20960486 [TBL] [Abstract][Full Text] [Related]
51. Comparison of enteric-coated levodopa with levodopa-carbidopa combination. A double-blind crossover trial. Gilligan B; Wodak J; Stark R; O'Halloran M Med J Aust; 1979 Aug; 2(4):205-7. PubMed ID: 390336 [TBL] [Abstract][Full Text] [Related]
52. Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. Warren Olanow C; Torti M; Kieburtz K; Leinonen M; Vacca L; Grassini P; Heller A; Heller E; Stocchi F Mov Disord; 2019 Mar; 34(3):425-429. PubMed ID: 30653246 [TBL] [Abstract][Full Text] [Related]
53. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease. Delea TE; Thomas SK; Hagiwara M; Mancione L Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819 [TBL] [Abstract][Full Text] [Related]
54. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. Sage JI; Mark MH Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226 [No Abstract] [Full Text] [Related]